Iguratimod

Iguratimod is an antirheumatic agent, acts as an inhibitor of COX-2, with an IC50 of 20 μM (7.7 μg/mL), but shows no effect on COX-1. Iguratimod also inhibits macrophage migration inhibitory factor (MIF) with an IC50 of 6.81 μM.

Product Specifications

CAS Number

[123663-49-0]

Product Name Alternative

T614

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

COX; Macrophage migration inhibitory factor (MIF)

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/iguratimod.html

Purity

99.93

Solubility

DMSO : 33.33 mg/mL (ultrasonic)

Smiles

O=C1C2=CC(OC3=CC=CC=C3)=C(C=C2OC=C1NC([H])=O)NS(=O)(C)=O

Molecular Formula

C17H14N2O6S

Molecular Weight

374.37

Precautions

H302, H315, H319, H335

References & Citations

[1]Tanaka K, et al. T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts. Jpn J Pharmacol. 1995 Apr;67 (4) :305-14.|[2]Sun Y, et al. Anti-rheumatic drug iguratimod protects against cancer-induced bone pain and bone destruction in a rat model. Oncol Lett. 2017 Jun;13 (6) :4849-4856.|[3]Iguratimod, et al. Identification of Iguratimod as an Inhibitor of Macrophage Migration Inhibitory Factor (MIF) with Steroid-sparing Potential. J Biol Chem. 2016 Dec 16;291 (51) :26502-26514.